- 首頁
- App 分析
- COAPT Risk Score
- COAPT Risk Score Vs. ManageMR
COAPT Risk Score 與 ManageMR 使用情況與統計
For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy.
The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER.
Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
ManageMR provides clinicians with personalized referral and treatment advice for diagnosed mitral regurgitation patients by verifying the severity and etiology of the MR.
• Enter patient parameters from an echo assessment.
• Review customized advice on
- Probable severity and etiology of a patient’s MR
- Need for referral
- Feasibility of mitral valve repair vs. replacement for the patient
Content in this app is derived from the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation. The information and advice in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider. ManageMR is part of the ManageMR Toolkit supported by Founding Sponsor Abbott Vascular.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
COAPT Risk Score與 ManageMR 比較排名
比較過去 28 天的 COAPT Risk Score 排名趨勢與 ManageMR
排名
無可用數據
各國 COAPT Risk Score vs. ManageMR 排名比較
比較過去 28 天的 COAPT Risk Score 排名趨勢與 ManageMR
無可顯示數據
使用我們的免費試用版,與所有網站進行比較
COAPT Risk Score VS.
ManageMR
12月 19, 2024